LeadStory

CNBC

Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel

CNBC · Just In
CNBC
CNBC
Just In

CNBC’s “Fast Money” team discusses new obesity drug data and the market leaders, including Novo Nordisk and Eli Lilly, with Dr. Kavita Patel, NBC News and MSNBC medical contributor.

Breakdown
  • Novo Nordisk's new data on obesity treatments is generating positive attention. 49s
  • Cost, side effects, and medication adherence are major factors for prescribers. 1m 2s
  • Companies are developing different formulations and dosing to meet varied patient needs. 1m 28s
  • Patients are adjusting doses to balance weight loss goals and side effects. 2m 8s
  • Muscle loss with significant fat loss is a concern being addressed in ongoing trials. 2m 27s
HealthBusiness